UR Faculty: Janet D. Sparks

Ph.D. (1980) University of Pennsylvania	Janet D. Sparks Associate Professor of Pathology and Laboratory Medicine Primary Appointment: Pathology and Labratory Medicine GEBS Cluster Affiliations: PWD - Pathways of Human Disease
Research: Insulin Regulation of Hepatic Lipoprotein Production Through Phosphatidylinositide-3-Kinase Activation Via Insulin Receptor Signaling Pathways
Contact Information: E-Mail: Janet_Sparks@urmc.rochester.edu
University of Rochester School of Medicine and Dentistry 601 Elmwood Ave, Box 626 Rochester, New York 14642	Medical Center B-7653 Phone: (585) 275-7755

Research Overview

Plasma lipoproteins are the major vehicles for non-aqueous transport of lipids, including cholesterol and triglyceride, and lipid-soluble vitamins such as vitamin A and E, from the liver and intestine to tissues. Derangements in lipoprotein metabolism are involved in progression of atherosclerosis, an underlying cause of heart disease and strokes which remain the major cause of death in the United States. Insulin, known as a key regulator in carbohydrate metabolism, plays a major regulatory role in hepatic lipoprotein metabolism. Insulin acts by inhibition of secretion of triglyceride-rich lipoproteins through a mechanism involving the stimulation of the intracellular degradation of apolipoprotein B, an essential structural apolipoprotein. Research in my laboratory links specific events involved in insulin receptor (IR) signal transduction with microsomal events that lead to degradation of apo B. The focus is on insulin-activated phosphatidylinositide 3-kinase (PI-3-kinase) in the translocation of apo B and its intracellular transport within the secretory pathway. Investigations employ primary rat hepatocytes, McArdle RH-7777 rat hepatoma cells and HepG2 cells and assay of IR signaling, Beta-subunit phosphorylation, IRS phosphorylation, PI 3-K activation and of PI 3-K mass in subcellular fractions. Progress will allow better understanding of insulin regulation of triglyceride-rich lipoprotein secretion by liver and will provide insights into the mechanisms involved in the development of hypertriglyceridemia in human obesity and insulin resistance syndromes such as metabolic Syndrome X which increase the risk of atherosclerosis complications up to ten times.

Recent Publications

SPARKS JD and SPARKS CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochem. Biophys. Acta 1215: 9-32 (1994). Review article.

SPARKS JD, PHUNG TL (pre-doctoral fellow), BOLOGNINO M and SPARKS CE: Insulin-mediated inhibition of apo-lipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation. Studies using brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem. J. 313: 567-574 (1996).

PHUNG TL (pre-doctoral fellow), RONCONE A, DE MESY JENSEN KL, SPARKS CE and SPARKS JD: Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J. Biol. Chem. 272: 30693-30702 (1997).

Sparks JD, Bolognino M, Khurana R, Peterson RG, Corsetti JC and Sparks CE: Lipoprotein alterations in 10 and 20 week Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia. Metabolism 47: 1315-1324 (1998).

SPARKS JD, SHAW WN, BOLOGNINO M, CORSETTI JP, PESEK JF and SPARKS CE: Insulin-treated Zucker diabetic fatty rats retain the hypertriglyceridemia associated with obesity. Metabolism (2000) In press.

COLLINS HL (pre-doctoral fellow), SPARKS CE and SPARKS JD: B48 is preferentially translated over B100 in McArdle RH-7777 cells expressing increased endogenous apo B mRNA. Biochem. Biphys. Res. Commun. 273: 1156-1160 (2000).

CHIRIEAC DV (post-doctoral fellow) CHIRIEAC LR, CORSETTI JP, CIANCI J, SPARKS CE and SPARKS JD: Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apo B production in vivo. Amer. J. Physiol. 279: E1001-E1011 (2000).

FISHER EA, CHEN X, PAN M, WU X, WANG H, JAMIL H, SPARKS JD, WILLIAMS KJ: The triple threat to nascent apolipoprotein B: Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276:27855-27863 (2001).

CHIRIEAC DV, CIANCI J, COLLINS HL, SPARKS JD, SPARKS CE: Insulin suppression of VLDL apo B secretion is not mediated by the LDL receptor. Biochem. Biopys. Res. Commun. 297: 134-137 (2002).

AU CS, WAGNER A, CHONG T, QIU W, SPARKS JD, ADELI K. Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBalpha. Metabolism. 53(2):228-35 (2004). (PubMed)

CHIRIEAC DV, COLLINS HL, CIANCI J, SPARKS JD, and SPARKS CE. Altered triglyceride-rich lipoprotein production in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab. 287(1):E42-9 (2004). (PubMed)

PubMed is maintained by the National Library of Medicine and provides abstracts of publications as well as links to the full text of many articles (at journal homepages).

Pathology and Labratory Medicine Faculty

GEBS Clusters:

PWD